Using proprietary computing and data platforms, Sumitovant accelerates the development and commercialization of novel therapies for rare conditions and other diseases. With a diverse portfolio and scientific expertise, the company has supported the development of multiple FDA-approved products and has a robust pipeline of investigational assets targeting unmet needs in pediatrics, urology, oncology, women's health, specialty respiratory, and infectious diseases. Sumitovant is a wholly owned subsidiary of Sumitomo Pharma and takes a tech-enabled approach to drug discovery, development, and commercialization.